Researchers from Zymeworks Inc. recently reported preclinical data for ZW-220, an antibody-drug conjugate (ADC) consisting of humanized IgG1 monoclonal antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2, NaPi2b) conjugated to a topoisomerase I inhibitor, being developed for the treatment of cancer.

KAT6 is a histone lysine acetyl transferase involved in the epigenetic regulation of oncogenes and it is often dysregulated in cancer, including breast cancer. Inhibiting KAT6 blocks the transcription of genes such as ESR1 and CCND1 and the use of KAT6 inhibitors together with endocrine therapy and CDK4/6 inhibitor therapy may enhance the effectiveness in cancer.

Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.

At the Society for Immunotherapy of Cancer (SITC) meeting that ended yesterday in Houston, Dragonfly Therapeutics Inc. reported the first preclinical data on DF-6215, an alpha-active IL-2-Fc, for cancer immunotherapy.

IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that the overactivation of the lectin pathway contributes to the pathogenesis of IgA nephropathy.

Modified vaccinia Ankara immunization in nonhuman primate models of lethal mpox virus infection, although effective to some extent, has been linked to breakthrough lesions and throat swab viremia.

Data from preclinical studies conducted to evaluate the activity of NKT-3964, a first-in-class, orally bioavailable CDK2-selective PROTAC degrader being developed for the potential treatment of cancer, were reported by Nikang Therapeutics Inc.